RxDoctor Payments Data

Nhuai le, MD

Internal Medicine · Houston, TXNPI 1558358697

Payments from drug & device makers

$3,281in general payments, 2019–2025

Across 208 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$823
  • Novo Nordisk$564
  • AstraZeneca$466
  • Boehringer Ingelheim$347
  • Sanofi-aventis U.S. LLC$234
  • Amneal Pharmaceuticals LLC$127
  • plus $720 from 18 others

What the payments were for

  • Food & beverage$3,266100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,281 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$143,387
Medicare patients
308
Services billed
1,976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide139$178,760
MounjaroTirzepatide34$40,206
XareltoRivaroxaban33$39,642
JardianceEmpagliflozin31$34,670
FarxigaDapagliflozin Propanediol30$24,716
JanuviaSitagliptin Phosphate26$22,348
GemtesaVibegron15$17,611
EliquisApixaban12$16,394
Janumet XrSitagliptin Phos/Metformin Hcl12$15,057
LinzessLinaclotide14$13,902
SynthroidLevothyroxine Sodium157$13,748
MyrbetriqMirabegron11$10,178
Advair HfaFluticasone Propion/Salmeterol14$5,047
Risedronate Sodium54$4,690
VyvanseLisdexamfetamine Dimesylate12$4,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$564$178,760139 claims
Lilly USA, LLCMounjaro$119$40,20634 claims
MerckJanuvia, Janumet Xr$42$37,40538 claims
Boehringer IngelheimJardiance$347$34,67031 claims
AbbVieLinzess, Synthroid$823$27,650171 claims
AstraZenecaFarxiga$466$24,71630 claims
Sumitomo Pharma America, Inc.Gemtesa$48$17,61115 claims
Astellas Pharma US IncMyrbetriq$38$10,17811 claims
Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium$127$3,151173 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →